Literature DB >> 7784283

Severe theophylline poisoning: charcoal haemoperfusion or haemodialysis?

R M Higgins1, S Hearing, D J Goldsmith, B Keevil, M C Venning, P Ackrill.   

Abstract

Theophylline poisoning with a blood level of 183 mg/l in a 38-year-old man was treated with activated charcoal by mouth, but despite this the blood level of theophylline rose and there was circulatory collapse with rhabdomyolysis, acute renal failure and hyperthermia. Treatment with charcoal haemoperfusion and simultaneous haemodialysis was given, followed by continuous arteriovenous haemodialysis (CAVHD). Mean extraction rates of theophylline were 26% during CAVHD, and 86% during combined dialysis and charcoal haemoperfusion. During combined treatment, the mean extraction rate of haemodialysis was 62%, compared with 48% for charcoal haemoperfusion. In summary, activated charcoal given by mouth may be unable to prevent a rise in blood levels and the development of complications after substantial theophylline overdose. If theophylline is to be removed from the blood, a combination of charcoal haemoperfusion and haemodialysis will give the best clearance, but haemodialysis alone may be effective.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784283      PMCID: PMC2398059          DOI: 10.1136/pgmj.71.834.224

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  Acute compartment syndrome secondary to theophylline overdose.

Authors:  D M Lloyd; S P Payne; C R Tomson; M R Barnes; M J Allen
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

2.  How useful is activated charcoal?

Authors:  J A Vale; A T Proudfoot
Journal:  BMJ       Date:  1993-01-09

3.  Management of theophylline intoxication with charcoal-column hemoperfusion.

Authors:  M E Russo
Journal:  N Engl J Med       Date:  1979-01-04       Impact factor: 91.245

4.  Self-poisoning with sustained-release aminophylline: secondary rise in serum theophylline concentration after charcoal haemoperfusion.

Authors:  J M Connell; J F McGeachie; J Knepil; A Thomson; B Junor
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

5.  Haemoperfusion for theophylline overdose.

Authors:  D B Jefferys; S M Raper; M Helliwell; D J Berry; P Crome
Journal:  Br Med J       Date:  1980-05-10

6.  Massive theophylline overdose. Rapid elimination by charcoal hemoperfusion.

Authors:  S M Ehlers; D E Zaske; R J Sawchuk
Journal:  JAMA       Date:  1978-08-04       Impact factor: 56.272

7.  Use of hemoperfusion for treatment of theophylline intoxication.

Authors:  G D Park; R Spector; R J Roberts; M J Goldberg; D Weismann; A Stillerman; M J Flanigan
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965

8.  Model for theophylline overdose treatment with oral activated charcoal.

Authors:  L Radomski; G D Park; M J Goldberg; R Spector; G F Johnson; C K Quee
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

9.  Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.

Authors:  C S Lee; J C Peterson; T C Marbury
Journal:  J Clin Pharmacol       Date:  1983-07       Impact factor: 3.126

10.  Increased serum theophylline clearance with orally administered activated charcoal.

Authors:  C K Mahutte; R J True; T M Michiels; J M Berman; R W Light
Journal:  Am Rev Respir Dis       Date:  1983-11
View more
  3 in total

Review 1.  Poisoning in children 1: general management.

Authors:  M Riordan; G Rylance; K Berry
Journal:  Arch Dis Child       Date:  2002-11       Impact factor: 3.791

2.  Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity.

Authors:  Julia Fisher; Andis Graudins
Journal:  J Med Toxicol       Date:  2015-09

3.  Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Simon Klimovic; Martin Scurek; Martin Pesl; Deborah Beckerova; Sarka Jelinkova; Tomas Urban; Daniil Kabanov; Zdenek Starek; Marketa Bebarova; Jan Pribyl; Vladimir Rotrekl; Kristian Brat
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.